149 related articles for article (PubMed ID: 18692873)
1. Phase II trial of capecitabine and weekly docetaxel in metastatic renal cell carcinoma.
Marur S; Eliason J; Heilbrun LK; Dickow B; Smith DW; Baranowski K; Alhasan S; Vaishampayan U
Urology; 2008 Oct; 72(4):898-902. PubMed ID: 18692873
[TBL] [Abstract][Full Text] [Related]
2. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
Mackey JR; Tonkin KS; Koski SL; Scarfe AG; Smylie MG; Joy AA; Au HJ; Bodnar DM; Soulieres D; Smith SW
Clin Breast Cancer; 2004 Oct; 5(4):287-92. PubMed ID: 15507175
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer.
Vaishampayan UN; Marur S; Heilbrun LK; Cher ML; Dickow B; Smith DW; Al Hasan SA; Eliason J
J Urol; 2009 Jul; 182(1):317-23. PubMed ID: 19447430
[TBL] [Abstract][Full Text] [Related]
5. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
Bellmunt J; Trigo JM; Calvo E; Carles J; Pérez-Gracia JL; Rubió J; Virizuela JA; López R; Lázaro M; Albanell J
Lancet Oncol; 2010 Apr; 11(4):350-7. PubMed ID: 20163987
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas.
Lo SS; Khorana AA; Javle M; Simon S; Kiefer G; Rajasenan K; Wang H; Hantel A; Shayne M; Hwang J; Schmotzer A; Ramanathan RK
Oncology; 2010; 78(2):125-9. PubMed ID: 20389134
[TBL] [Abstract][Full Text] [Related]
7. Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
Puglisi F; Cardellino GG; Crivellari D; Di Loreto C; Magri MD; Minisini AM; Mansutti M; Andreetta C; Russo S; Lombardi D; Perin T; Damante G; Veronesi A
Ann Oncol; 2008 Sep; 19(9):1541-6. PubMed ID: 18441329
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity.
Segota E; Mekhail T; Olencki T; Hutson TE; Dreicer R; Wacker B; Osterwalder B; Elson P; Zhou M; Bukowski RM
Urol Oncol; 2007; 25(1):46-52. PubMed ID: 17208138
[TBL] [Abstract][Full Text] [Related]
9. A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer.
Bayo J; Lomas M; Salvador J; Moreno A; Ruiz M; Rodríguez A; Fuentes J; Fernández-Freire A; Bernabé R; Fernández A
Clin Transl Oncol; 2008 Dec; 10(12):817-25. PubMed ID: 19068453
[TBL] [Abstract][Full Text] [Related]
10. Phase II, multicenter, uncontrolled trial of single-agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma.
Tsimafeyeu I; Demidov L; Kharkevich G; Petenko N; Galchenko V; Sinelnikov I; Naidzionak U
Am J Clin Oncol; 2012 Jun; 35(3):251-4. PubMed ID: 21358295
[TBL] [Abstract][Full Text] [Related]
11. Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study.
Rosati G; Bilancia D; Germano D; Dinota A; Romano R; Reggiardo G; Manzione L
Ann Oncol; 2007 Jun; 18 Suppl 6():vi128-32. PubMed ID: 17591806
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
Tagawa ST; Milowsky MI; Jeske S; Mazumdar M; Kung S; Sung M; Lehrer D; Matulich D; Selzer J; Wright JJ; Nanus DM
Am J Clin Oncol; 2011 Oct; 34(5):443-8. PubMed ID: 20881475
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC).
Bertino EM; Bekaii-Saab T; Fernandez S; Diasio RB; Karim NA; Otterson GA; Villalona-Calero MA
Lung Cancer; 2013 Jan; 79(1):27-32. PubMed ID: 23079156
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma.
Han JY; Lee DH; Kim HY; Hong EK; Yoon SM; Chun JH; Lee HG; Lee SY; Shin EH; Lee JS
Cancer; 2003 Nov; 98(9):1918-24. PubMed ID: 14584075
[TBL] [Abstract][Full Text] [Related]
15. Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre.
Jonasch E; Lal LS; Atkinson BJ; Byfield SD; Miller LA; Pagliaro LC; Feng C; Tannir NM
BJU Int; 2011 Mar; 107(5):741-747. PubMed ID: 21355978
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma.
Wenzel C; Locker GJ; Bartsch R; Pluschnig U; Mader R; Hussian D; Kramer G; Marberger M; Lintner C; Rauchenwald M; Zielinski CC; Steger GG
Anticancer Drugs; 2003 Nov; 14(10):779-84. PubMed ID: 14597871
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.
Tannir NM; Thall PF; Ng CS; Wang X; Wooten L; Siefker-Radtke A; Mathew P; Pagliaro L; Wood C; Jonasch E
J Urol; 2008 Sep; 180(3):867-72; discussion 872. PubMed ID: 18635226
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
[TBL] [Abstract][Full Text] [Related]
19. A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer.
Sunela KL; Koskinen S; Kellokumpu-Lehtinen PL
Cancer Chemother Pharmacol; 2010 May; 66(1):59-67. PubMed ID: 19771431
[TBL] [Abstract][Full Text] [Related]
20. The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
Harshman LC; Li M; Srinivas S
Am J Clin Oncol; 2008 Oct; 31(5):417-23. PubMed ID: 18838876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]